ANAVEX LIFE SCIENCES CORP. 8-K

What Happened
On March 25, 2026, Anavex Life Sciences Corp. announced it has withdrawn its application for marketing authorization of blarcamesine in the European Union. The application was for blarcamesine as an add‑on therapy for the treatment of early Alzheimer’s disease in adults and had been under review by the European Medicines Agency (EMA). The company furnished a press release dated March 25, 2026 (Exhibit 99.1) announcing the withdrawal.

Key Details

• Date of announcement: March 25, 2026.
• Drug and indication: blarcamesine as an add‑on therapy for early Alzheimer’s disease in adults.
• Regulatory body: Application under review by the European Medicines Agency (EMA) was withdrawn.
• Filing details: Announcement made via Form 8‑K (Item 8.01); press release furnished as Exhibit 99.1.

Why It Matters
This is a regulatory setback for Anavex’s EU commercialization plans for blarcamesine. Withdrawal of the EMA application removes a pathway to market in the EU for this indication and may affect timelines for potential product sales or partnership opportunities in Europe. The 8‑K does not report financial results, management changes, or other disclosures beyond the press release; investors should look for further company communications for next steps or explanations behind the withdrawal.